Bio Historical Income Statement
| BIO Stock | USD 332.91 7.33 2.25% |
Historical analysis of Bio Rad income statement accounts such as Interest Expense of 51.9 M, Selling General Administrative of 481.6 M or Total Revenue of 1.4 B can show how well Bio Rad Laboratories performed in making a profits. Evaluating Bio Rad income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bio Rad's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bio Rad Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Rad Laboratories is a good buy for the upcoming year.
Bio |
About Bio Income Statement Analysis
Bio Rad Laboratories Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bio Rad shareholders. The income statement also shows Bio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bio Rad Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Bio Rad Laboratories generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Bio Rad Laboratories minus its cost of goods sold. It is profit before Bio Rad operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bio Rad Laboratories. It is also known as Bio Rad overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Bio Rad's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Bio Rad's Net Interest Income is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.6B | 1.4B | 769.3M | Total Revenue | 2.9B | 2.8B | 2.7B | 1.4B |
Bio Rad income statement Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 160.3M | 175.2M | 176.9M | 177.2M | 192.4M | 202.0M | |
| Interest Expense | 23.4M | 21.9M | 1.6M | 38.1M | 49.4M | 51.9M | |
| Selling General Administrative | 824.6M | 800.3M | 879.6M | 827.8M | 846.8M | 481.6M | |
| Total Revenue | 2.3B | 2.5B | 2.9B | 2.8B | 2.7B | 1.4B | |
| Gross Profit | 1.3B | 1.4B | 1.6B | 1.6B | 1.4B | 769.3M | |
| Other Operating Expenses | 2.1B | 2.1B | 2.4B | 2.3B | 2.3B | 1.2B | |
| Operating Income | 229.7M | 411.0M | 489.4M | 482.6M | 383.8M | 403.0M | |
| Ebit | 229.7M | 4.9B | 5.5B | (4.7B) | (800.7M) | (760.6M) | |
| Ebitda | 390.0M | 5.1B | 5.6B | (4.5B) | (608.3M) | (577.9M) | |
| Cost Of Revenue | 1.1B | 1.1B | 1.3B | 1.2B | 1.2B | 1.3B | |
| Total Operating Expenses | 1.0B | 1.0B | 1.2B | 1.1B | 1.0B | 613.7M | |
| Income Before Tax | 2.3B | 4.9B | 5.4B | (4.7B) | (850.1M) | (807.6M) | |
| Total Other Income Expense Net | 2.0B | 4.5B | 4.9B | (5.2B) | (1.2B) | (1.2B) | |
| Net Income | 1.8B | 3.8B | 4.3B | (3.6B) | (637.3M) | (605.5M) | |
| Income Tax Expense | 502.4M | 1.1B | 1.2B | (1.1B) | (212.8M) | (202.1M) | |
| Research Development | 202.7M | 226.6M | 271.7M | 256.9M | 226.9M | 161.8M | |
| Net Income Applicable To Common Shares | 1.8B | 3.8B | 4.2B | (3.6B) | (4.2B) | (4.0B) | |
| Net Income From Continuing Ops | 1.8B | 3.8B | 4.2B | (3.6B) | (159.3M) | (151.3M) | |
| Non Operating Income Net Other | 23.8M | 22.7M | 24.0M | 44.8M | 51.5M | 54.1M | |
| Tax Provision | 502.4M | 1.1B | 1.2B | (1.1B) | (27.9M) | (26.5M) | |
| Interest Income | 30.5M | 4.5B | 4.9B | 58M | 96.4M | 91.6M | |
| Net Interest Income | 7.1M | (21.9M) | (1.6M) | 19.9M | 47.6M | 50.0M |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.4 | VCNX | Vaccinex | PairCorr |
| 0.4 | FBRX | Forte Biosciences Trending | PairCorr |
| 0.38 | VALN | Valneva SE ADR | PairCorr |
| 0.35 | HLN | Haleon plc | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.